title: Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients.
abstract: OBJECTIVE
  To evaluate the impact of the DRD2 TaqIA and DRD3 Ser9Gly polymorphisms on the efficacy of pramipexole in treating patients with Parkinson's disease (PD).
  
  
  METHODS
  Thirty patients with PD prospectively received pramipexole 0.25 mg three times daily for 2 months. Unified Parkinson Disease Rating Scale (UPDRS) assessments were conducted at baseline and 2 months after treatment initiation. Improvement by 20% or more in the total score on the UPDRS was considered to indicate responsiveness. The PCR-restriction fragment length polymorphism analysis was used to analyze the DRD2 Taq1A and DRD3 Ser9Gly genotype.
  
  
  RESULTS
  The DRD2 Taq1A allele frequencies were A141.7 (A1) and 58.3% (A2), and the DRD3 Ser9Gly allele frequencies were 68.3 (Ser) and 31.7% (Gly). When the subjects were grouped by the DRD3 Ser9Gly polymorphism, the response rates for pramipexole treatment were significantly higher in the Ser/Ser group (60%) than in the group containing the Gly allele (13%). There was a significant association between the DRD3 Ser9Gly polymorphism and response rate to pramipexole in PD patients (P = 0.024). When the subjects were grouped by the DRD2 Taq1A polymorphism, there were no significant differences among the three Taq1A genotypes.
  
  
  CONCLUSIONS
  DRD3 Ser9Gly polymorphisms are significantly associated with the therapeutic efficacy of pramipexole in Chinese patients with PD. A large-scale and multi-dose group study in patients with PD is necessary for evaluating the impact of the genetic polymorphisms of the dopamine receptor on the therapeutic effects of pramipexole.
authors.affiliation: Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, 410078, China.
authors.forename: Ying-Zi
authors.initials: YZ
authors.lastname: Liu
authors.forename: Bei-Sha
authors.initials: BS
authors.lastname: Tang
authors.forename: Xin-Xiang
authors.initials: XX
authors.lastname: Yan
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.forename: Dong-Sheng
authors.initials: DS
authors.lastname: Ouyang
authors.forename: Li-Nuo
authors.initials: LN
authors.lastname: Nie
authors.forename: Lan
authors.initials: L
authors.lastname: Fan
authors.forename: Zhi
authors.initials: Z
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Ji
authors.forename: Dong-Li
authors.initials: DL
authors.lastname: Hu
authors.forename: Dan
authors.initials: D
authors.lastname: Wang
authors.forename: Hong-Hao
authors.initials: HH
authors.lastname: Zhou
mesh_terms: D000368:Aged; D000483:Alleles; D044466:Asian People / Q000706:statistics & numerical data; D052160:Benzothiazoles / Q000627:therapeutic use*; D004247:DNA / Q000097:blood / Q000235:genetics / Q000302:isolation & purification; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011110:Polymorphism, Genetic; D000077487:Pramipexole; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D050637:Receptors, Dopamine D3 / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D052160:Benzothiazoles; D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; D000077487:Pramipexole; D004247:DNA